- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03606538
MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function
A Phase I, Open Label, Study of 3,4-Methylenedioxymethamphetamine (MDMA) Tolerability and Pharmacokinetics in Subjects With Moderate Hepatic Impairment Compared to Matched Control Subjects With Normal Hepatic Function
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PTSD is a serious debilitating disorder that negatively impacts a person's daily life. 3,4-methylenedioxymethamphetamine (MDMA) is a ring-substituted phenylisopropylamine derivative that releases serotonin, norepinephrine and dopamine. MDMA has been shown to reduce defenses and fear of emotional injury, enhance communication, and increase empathy, creating productive psychological state that enhances the therapeutic process for the treatment of PTSD and other anxiety disorders. This is supported by data from an international series of Phase 2 pilot studies of MDMA-assisted psychotherapy conducted by the sponsor that provide preliminary evidence that chronic PTSD, independent of cause, is treatable with two to three sessions of MDMA-assisted psychotherapy and associated non-drug preparatory and integrative psychotherapy. The results from multiple independent studies in Phase 2 efficacy analyses demonstrate superiority of MDMA-assisted psychotherapy over psychotherapy with placebo and low dose MDMA.
This protocol is for a Phase 1, open-label study with a primary purpose of evaluating the effect of moderate hepatic impairment in the pharmacokinetics of MDMA and its active metabolite, 3,4-methylene-dioxyamphetamine (MDA), and determining whether an adjustment to the dosage would be indicated in this group of patients in comparison to patients with normal liver function. Because people with moderate hepatic impairment may experience greater exposure to drug than people without it, the secondary purpose of this study is to evaluate the effect of moderate hepatic impairment on the safety and tolerability of oral MDMA, with special attention to ECG data. The study will enroll eight participants, ages 18 to 65 years old, with moderate hepatic impairment, and eight healthy controls with normal hepatic function who are matched with participants with moderate impaired hepatic function on the basis of age, weight and gender.
Participants who give their written informed consent will be screened for study participation that will include a physical examination, assessing current and prior medical and physical health, and a baseline electrocardiogram (ECG) reading. If applicable, they may begin tapering off any contraindicated psychiatric medication. Participants who meet study criteria will receive a single dose of 80 mg MDMA on the first day of a three-day stay at the study site. Blood will be collected periodically in order to calculate pharmacokinetics of MDMA and its active metabolite methylenedioxyamphetamine (MDA). Blood will be collected ten times on Day 1 (-5 min, 0 hours (drug administration), 0.5 h, 1, 2, 4, 6, 7, 10 and 12 hours), starting five minutes before drug administration. Subjective effects of MDMA will be assessed through 15 visual analog scales at similar time points to blood collection, at 0.5, 1, 2, 4, 6 and 7 hours post-drug. There will be six 12-lead ECG measurements on Day 1. Participants will remain at the study site for two more days. Drug safety will be assessed by measuring blood pressure, heart rate and body temperature after MDMA administrations, collecting adverse events throughout the study and measuring suicidal thoughts or behaviors with the Columbia Suicide Severity Rating Scale (C-SSRS). Blood will be collected 24 and 36 hours after drug administration, and ECG will be performed on Day 2, and a single ECG and blood draw will occur on Day 3, 4 and 5. Participants will return for eight and 15 days after drug administration. They will have a single blood draw on each day. The study ends 15 days after drug administration, approximately one month after screening.
The primary outcome measure will be area under the curve from dosing to last dose (AUC) of MDMA and MDA. AUC will be computed from plasma collected multiple times after a single dose of MDMA, twice on the day following the day of drug administration, and once daily for three more days. Other pharmacokinetic measures will be maximal values of MDMA and MDA (Cmax), and time to reach maximum MDMA and MDA levels (Tmax). Safety measures will also include a comparison of subjective effects across groups, ECG readings, number of adverse events, and suicidal ideation or behavior as measured via C-SSRS during the study.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Recruitment Officer
- Phone Number: (215) 645-2466
- Email: recruitment@mapsbcorp.com
Study Locations
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- Alliance for Multispecialty Research, LLC.
-
Contact:
- Study Coordinator
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants with moderate hepatic impairment (class B according to Child- Pugh's criteria).
- Participants with normal hepatic function: no clinically significant findings from medical history, physical examination, laboratory values within protocol defined parameters.
- Age 18 to 65 years.
- Weight > 45 kg
- Negative Carbohydrate Deficient Transferrin blood test at Screening and negative breathalyzer alcohol test prior to trial drug administration.
- Negative urine test for drugs of abuse at Screening and prior to trial drug administration.
- Able to comprehend and willing to sign an informed consent form.
Exclusion Criteria:
- Have a current psychiatric diagnosis.
- Are pregnant or nursing, or are women of child bearing potential who are not practicing an effective means of birth control.
- Have acute or exacerbating hepatitis, fluctuating or rapidly deteriorating hepatic function as indicated by widely varying or worsening of clinical and/or laboratory signs of hepatic impairment within 2 weeks.
- Have autoimmune liver disease; esophageal variceal bleeding within 6 months prior to screening, unless successfully treated with banding, or gastric varices.
- Have spontaneous bacterial peritonitis within 3 months prior to screening.
- Have a portosystemic shunt, organ transplant, Wilson's disease, cholestatic liver disease (e g, primary biliary cirrhosis or primary sclerosing cholangitis)
- Evidence or history of significant hematological, endocrine, cerebrovascular, cardiovascular (including controlled hyper-tension), coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder, or any other medical disorder judged by the investigator to significantly increase the risk of MDMA administration.
- For moderate hepatic impairment participants: have clinically significant laboratory findings except as related to hepatic impairment.
- For control participants only: have clinically significant laboratory results outside the normal limits, including AST >48 U/L, ALT > 55 U/L, GGT > 48 U/L, bilirubin > 1.2 mg/dL or hemoglobin < 12 g/dL.
- Have a history of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose risk in administering the trial drug to the subject.
- Have any positive test for drugs of abuse and /or alcohol at screening.
- Have a history or presence of clinically significant abnormal 12-lead ECG or an ECG with QTc by Bazett's correction of > 450 ms in men, > 470 ms in women on the screening ECG.
- Have a PR interval > 240 ms, QRS > 110 ms or a history of prolongation of QT interval.
- Have mental incapacity, unwillingness or language barriers precluding adequate understanding or subject co-operation.
- Are unwilling to stay in the clinical unit for the required duration as per the protocol.
- Have a history of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
- Have a known or suspected allergy to trial product or related products.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Moderate hepatic impairment
Eight participants with moderate hepatic impairment receive a single dose of 80 mg MDMA.
|
80 mg MDMA
Other Names:
|
Experimental: Normal hepatic function
Eight participants, each matched on age, weight and gender to a participant with moderate hepatic impairment, receive a single dose of 80 mg MDMA.
|
80 mg MDMA
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under curve from dosing time to last measurement (AUC(0-t)) - MDMA
Time Frame: 0 to 5 days after drug administration
|
Computed exposure to MDMA using blood collected periodically at 1, 2, 4, 6, 7, 10, 12, 24, 36, 48, 72 and 96 h post drug
|
0 to 5 days after drug administration
|
Area under curve from dosing time to last measurement (AUC(0-t) MDA
Time Frame: 0 to 5 days after drug administration
|
Computed exposure to MDA using blood collected periodically at 1, 2, 4, 6, 7, 10, 12, 24, 36, 48, 72 and 96 h post-MDMA administration
|
0 to 5 days after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak MDMA (Cmax)
Time Frame: 0 to 5 days after drug administration
|
Maximum value of plasma MDMA in nglml
|
0 to 5 days after drug administration
|
Peak MDA (Cmax)
Time Frame: 0 to 5 days after drug administration
|
Maximum value of plasma MDA in ng/lml
|
0 to 5 days after drug administration
|
Time to maximum (Tmax) MDMA
Time Frame: 0 to 5 days after drug administration
|
Time to reach maximum plasma values of MDMA
|
0 to 5 days after drug administration
|
Time to maximum (Tmax) MDA
Time Frame: 0 to 5 days after drug administration
|
Time to reach maximum plasma values of MDA
|
0 to 5 days after drug administration
|
Area under curve from dosing time to infinity (AUC(0-infinity)) - MDMA
Time Frame: 0 to 5 days after drug administration
|
Computed exposure to MDMA using blood collected periodically at 1, 2, 4, 6, 7, 10, 12, 24, 36, 48, 72 and 96 h post drug
|
0 to 5 days after drug administration
|
Area under curve from dosing time to infinity (AUC(0-infinity)) - MDA
Time Frame: 0 to 5 days after drug administration
|
Computed exposure to MDA using blood collected periodically at 1, 2, 4, 6, 7, 10, 12, 24, 36, 48, 72 and 96 h post drug
|
0 to 5 days after drug administration
|
90% CL between hepatic impaired and no hepatic impairment groups for AUC (0-t)
Time Frame: 0 to 5 days after drug administration
|
90% confidence interval (CI) for the ratio of population geometric means between moderate hepatic impairment and normal hepatic function for AUC (0-t)
|
0 to 5 days after drug administration
|
90% CL between hepatic impaired and no hepatic impairment groups for AUC (0-infinity)
Time Frame: 0 to 5 days after drug administration
|
90% confidence interval (CI) for the ratio of population geometric means between moderate hepatic impairment and normal hepatic function for AUC(0-infinity)
|
0 to 5 days after drug administration
|
90% CL between hepatic impaired and no hepatic impairment groups for Cmax
Time Frame: 0 to 5 days after drug administration
|
90% confidence interval (CI) for the ratio of population geometric means between moderate hepatic impairment and normal hepatic function for Cmax
|
0 to 5 days after drug administration
|
Change in QTcI - Baseline to 0.5 h post drug
Time Frame: 0 days after drug administration
|
Change in ECG QTcl from Baseline compared to 0.5 h post MDMA
|
0 days after drug administration
|
Change in QTcI - Baseline to 2 h post-drug
Time Frame: 0 days after drug administration
|
Change in ECG QTcl from Baseline compared to 2 h post MDMA
|
0 days after drug administration
|
Change in QTcI Baseline to 4 h post-drug
Time Frame: 0 days after drug administration
|
Change in ECG QTcl from Baseline compared to 4 h post MDMA
|
0 days after drug administration
|
Change in QTcI Baseline to 6 h post-drug
Time Frame: 0 days after drug administration
|
Change in ECG QTcl from Baseline compared to 6 h post MDMA
|
0 days after drug administration
|
Change in QTcI Baseline to 7 h post-drug
Time Frame: 0 days after drug administration
|
Change in ECG QTcl from Baseline compared to 7 h post MDMA
|
0 days after drug administration
|
Change in QTcI Baseline to 1 d post-drug
Time Frame: 1 day after drug administration
|
Change in ECG QTcl from Baseline compared to 1 d post MDMA
|
1 day after drug administration
|
Change in QTcI Baseline to 2 d post-drug
Time Frame: 2 days after drug administration
|
Change in ECG QTcl from Baseline compared to 2 d post MDMA
|
2 days after drug administration
|
Change in QTcI Baseline to 3 d post-drug
Time Frame: 3 days after drug administration
|
Change in ECG QTcl from Baseline compared to 3 d post MDMA
|
3 days after drug administration
|
Change in QTcI Baseline to 4 d post-drug
Time Frame: 4 days after drug administration
|
Change in ECG QTcl from Baseline compared to 4 d post MDMA
|
4 days after drug administration
|
Pre-drug Systolic blood pressure (SBP)
Time Frame: 0 days after drug administration
|
First SBP measurement, prior to drug administration, on day of drug administration
|
0 days after drug administration
|
Peak Systolic blood pressure (SBP)
Time Frame: 0 days after drug administration
|
Maximum value of SBP measured during day of drug administration
|
0 days after drug administration
|
Final systolic blood pressure (SBP)
Time Frame: 0 days after drug administration
|
Last SBP measurement taken on day of drug administration
|
0 days after drug administration
|
Pre-drug Diastolic blood pressure (DBP)
Time Frame: 0 days after drug administration
|
First DBP measurement, prior to drug administration, on day of drug administration
|
0 days after drug administration
|
Peak Diastolic blood pressure (DBP)
Time Frame: 0 days after drug administration
|
Maximum value of DBP measured during day of drug administration
|
0 days after drug administration
|
Final Diastolic blood pressure (DBP)
Time Frame: 0 days after drug administration
|
Last DBP measurement taken on day of drug administration
|
0 days after drug administration
|
Pre-drug heart rate (HR)
Time Frame: 0 days after drug administration
|
First HR measurement, prior to drug administration, on day of drug administration
|
0 days after drug administration
|
Peak heart rate (HR)
Time Frame: 0 days after drug administration
|
Maximum value of HR measured during day of drug administration
|
0 days after drug administration
|
Final heart rate (HR)
Time Frame: 0 days after drug administration
|
Last HR measurement taken on day of drug administration
|
0 days after drug administration
|
Pre-drug body temperature (BT)
Time Frame: 0 days after drug administration
|
First body temperature measurement, prior to drug administration, on day of drug administration
|
0 days after drug administration
|
Peak body temperature (BT)
Time Frame: 0 days after drug administration
|
Maximum BT value measured during day of drug administration
|
0 days after drug administration
|
Final body temperature (BT)
Time Frame: 0 days after drug administration
|
Last BT measurement taken on day of drug administration
|
0 days after drug administration
|
Number of AEs reported
Time Frame: -4 days to 15 days post drug administration
|
Number of AEs reported in each group from enrollment to study end
|
-4 days to 15 days post drug administration
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Corine de Boer, MD, MAPS Public Benefit Corp.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Liver Diseases
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Hallucinogens
- Adrenergic Uptake Inhibitors
- N-Methyl-3,4-methylenedioxyamphetamine
Other Study ID Numbers
- MPKH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharmacokinetics
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Methotrexate | Pharmacokinetics of 7-hydroxymethotrexateUnited States
-
Astellas Pharma IncCompletedHealthy | Pharmacokinetics of ASP1941 | Pharmacokinetics of MitiglinideJapan
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of MethadoneUnited States
-
Astellas Pharma IncBasilea PharmaceuticaCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of MidazolamUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of DigoxinUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of BupropionUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of SirolimusUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of AtorvastatinUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Caffeine | Pharmacokinetics of RepaglinideUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of MetforminUnited States
Clinical Trials on Midomafetamine
-
Lykos TherapeuticsNo longer availablePost Traumatic Stress DisorderUnited States
-
Lykos TherapeuticsWithdrawnPosttraumatic Stress Disorder
-
Lykos TherapeuticsCompletedPosttraumatic Stress DisorderUnited States
-
Lykos TherapeuticsActive, not recruiting
-
Lykos TherapeuticsCompleted
-
Lykos TherapeuticsTerminatedPosttraumatic Stress DisorderCanada
-
Lykos TherapeuticsCompletedPsychological Effects of Study DrugUnited States
-
Lykos TherapeuticsCompletedPTSDUnited States, Canada, Israel
-
Lykos TherapeuticsTerminatedPosttraumatic Stress DisorderIsrael
-
Lykos TherapeuticsNot yet recruitingPsychological Effects of Study Drug